UBS Adjusts ResMed Price Target to $210 From $195, Maintains Neutral Rating
ResMed (RMD) has an average outperform rating and a price target range of $21.64 to $264, according to analysts polled by Capital IQ.Price: 205.06, Change: +1.18, Percent Change: +0.58
Express News | Resmed Inc : UBS Raises Target Price to $210 From $195
Do Weight Loss Drugs Pose a Threat to ResMed Shares?
ResMed Inc (ASX: RMD) shares have been under the spotlight recently after sliding from their previous highs of $33.10 apiece.
VARON Enters CPAP and BiPAP Machine Market With Feature-Rich "Sunny Grand" Series
SEATTLE, July 18, 2024 /PRNewswire/ -- VARON, a leading provider of oxygen concentrator solutions, is thrilled to announce the launch of its new line of CPAP (continuous positive airway pressure)
Returns On Capital Are A Standout For ResMed (NYSE:RMD)
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an eye out for. In a perfect world, we'd like to see a company investing more
Buy Resmed Shares at 'Attractive Entry Level' Says Top Broker
ResMed Inc (ASX: RMD) shares have been on an interesting journey this year to date.
Why the ResMed Share Price Tanked in FY 2024 and What to Expect in FY 2025
The ResMed Inc (ASX: RMD) share price hit some rough patches in the financial year just past.
Eli Lilly's GLP-1 Impact on ResMed Is Overblown: Barron's
GLP-1 Concerns Clobbered This Healthcare Stock. Now It's Time to Buy.
ResMed makes its bank from products that battle sleep apnea. When that business seemed threatened, investors fled. Now it looks like they were too hasty. By Jacob Sonenshine ResMed is the latest
Express News | Resmed Inc : BofA Global Research Raises Price Objective to $230 From $225
BofA Securities Maintains ResMed(RMD.US) With Buy Rating, Raises Target Price to $230
BofA Securities analyst Lyanne Harrison maintains $ResMed(RMD.US)$ with a buy rating, and adjusts the target price from $225 to $230.According to TipRanks data, the analyst has a success rate of 45.5%
Resmed Poised for Growth: Strong U.S. Device Sales and SaaS Segment to Drive Performance Despite Industry Challenges
Here's Why ResMed (RMD) Is a Strong Growth Stock
These Top ASX 200 Growth Shares Could Rise 20% to 45%
Fortunately for growth investors, there are a lot of quality options for them to choose from on the Australian share market.
ResMed(RMD.US) Officer Sells US$2.83 Million in Common Stock
$ResMed(RMD.US)$ Officer Farrell Michael J. sold 14,683 shares of common stock on Jul 8, 2024 at an average price of $192.9667 for a total value of $2.83 million.Source: Announcement What is
Insider Sale: CFO Brett Sandercock Sells Shares of ResMed Inc (RMD)
ResMed(RMD.US) Officer Sells US$194.35K in Common Stock
$ResMed(RMD.US)$ Officer Sandercock Brett sold 1,000 shares of common stock on Jul 8, 2024 at an average price of $194.35 for a total value of $194.35K.Source: Announcement What is statement of
Looking Into ResMed's Recent Short Interest
ResMed's (NYSE:RMD) short percent of float has fallen 16.56% since its last report. The company recently reported that it has 8.24 million shares sold short, which is 6.4% of all regular shares that
Form 144 | ResMed(RMD.US) Officer Proposes to Sell 2.83 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 8, $ResMed(RMD.US)$、$RESMED INC CDI COM USD0.004 (10CDI/1SHS)(RSMDF.US)$ Officer Farrell Michael J. intends to sell 14,683 shares of its common stock on Jul 8, with a total
Form 144 | ResMed(RMD.US) Officer Proposes to Sell 194.35K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 8, $ResMed(RMD.US)$、$RESMED INC CDI COM USD0.004 (10CDI/1SHS)(RSMDF.US)$ Officer Sandercock Brett intends to sell 1,000 shares of its common stock on Jul 8, with a total ma